Update | 5:51 p.m. Shares of Genentech climbed on Monday afternoon following reports that the biotechnology company was close to a deal to be acquired by Roche Holding for $95 a share. Genentech’s shares rose for …
“There’s a real opportunity that the next Genentech or Amgen will be …
Joe Biden
Genentech Inc.'s stock slipped 5.3% on Tuesday as investors winced at news that the U.S. attorney's office in Philadelphia was conducting an investigation into the marketing of the firm's top-selling drug, Rituxan. Shares …
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase program. It is …
Wall Street
Last year Genentech shares traded as high as nearly 88 dollars, but ended 2007 around 67 bucks. But according to the company's new proxy statement all of Genentech's top-tier executives saw their total compensation go …
The FDA on Thursday approved the first of a new class of cancer drugs that starves tumors by cutting off their blood supply. Avastin, developed by South San Francisco-based Genentech (DNA), was approved for …
Roche’s subsidiary Genentech Inc. is the innovator of monoclonal antibody (those made by identical immune cells that are all clones of a unique parent cell) trastuzumab, which is used primarily in the treatment of HER 2 …
breast cancer
Since Roche announced its intention to buy the outstanding shares of Genentech, everbody’s been wondering whether the company’s top scientists will bolt. Genentech put a retention plan in place yesterday — but the …
Biotech giant Genentech (NYSE: DNA) came public (again) today, jumping $30 from its $97 offering price to close at $127. For those of you who not familiar with the story, the Genentech stock traded over the past …
Morgan Stanley upgraded shares of Genentech to “overweight” from “equal weight” and said shares of the biotechnology leader look attractive at current prices. Analyst Steven Harr expects the stock market to rotate …